7月31日,礼来公司股价下跌4.9%,原因在于其重磅药物Mounjaro的心脏研究结果公布。该研究结果对市场信心产生直接影响,导致股价波动。Mounjaro是礼来重点推广的药物,其安全性与疗效备受关注。此次数据公布后,投资者担忧药物的市场前景及潜在风险。公司尚未对此作出进一步回应。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.